Park Jaeok, Pandya Vishal R, Ezekiel Sean J, Berghuis Albert M
Department of Biochemistry, Memorial University of Newfoundland, St. John's, NL, Canada.
Department of Biochemistry, McGill University, Montreal, QC, Canada.
Front Chem. 2021 Jan 6;8:612728. doi: 10.3389/fchem.2020.612728. eCollection 2020.
Phosphonates and bisphosphonates have proven their pharmacological utility as inhibitors of enzymes that metabolize phosphate and pyrophosphate substrates. The blockbuster class of drugs nitrogen-containing bisphosphonates represent one of the best-known examples. Widely used to treat bone-resorption disorders, these drugs work by inhibiting the enzyme farnesyl pyrophosphate synthase. Playing a key role in the isoprenoid biosynthetic pathway, this enzyme is also a potential anticancer target. Here, we provide a comprehensive overview of the research efforts to identify new inhibitors of farnesyl pyrophosphate synthase for various therapeutic applications. While the majority of these efforts have been directed against the human enzyme, some have been targeted on its homologs from other organisms, such as protozoan parasites and insects. Our particular focus is on the structures of the target enzymes and how the structural information has guided the drug discovery efforts.
膦酸盐和双膦酸盐已证明其作为代谢磷酸盐和焦磷酸盐底物的酶抑制剂的药理效用。重磅级药物含氮双膦酸盐就是最著名的例子之一。这些药物广泛用于治疗骨吸收疾病,其作用机制是抑制法尼基焦磷酸合酶。该酶在类异戊二烯生物合成途径中起关键作用,也是一个潜在的抗癌靶点。在此,我们全面概述了为确定用于各种治疗应用的法尼基焦磷酸合酶新抑制剂所做的研究工作。虽然这些努力大多针对人类酶,但也有一些针对来自其他生物体(如原生动物寄生虫和昆虫)的同源物。我们特别关注目标酶的结构以及结构信息如何指导药物研发工作。